Abstract:Background: The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In recent years, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have achieved remarkable efficacy in some lung cancer patients. Patients with EGFR mutations enjoyed limited benefits from immunotherapy according to recent studies. This study aimed to explore the relationship between EGFR mutation status and the spatial distribution as well as infiltration number of various immune cells in patients with EGFR mutant lung adenocarcinoma. Methods: This study included 62 lung adenocarcinoma patients who underwent surgery. Through multi-point sampling of surgically removed tumor tissues in different areas, 223 tumor tissue samples were finally obtained. We aquired EGFR mutations status including variant allele frequency (VAF) and mutation subtype in each tumor tissue by genetic test. Afterwards, hematoxylin-eosin (HE) staining, immunohistochemical staining and multiplex fluorescence immunohistochemistry staining have been performed, therefore the infiltration of various immune cells and the distribution of tertiary lymphoid structure (TLS) in tumor tissues were obtained by calculating the immunohistochemical score. Results: Compared with EGFR wild-type patients, patients with EGFR-mutant lung adenocarcinoma had more infiltration of CD68+ macrophages and major histocompatibility complex (MHC) class II antigen-presenting cells and higher spatial distribution heterogeneity of MHC class II antigen presenting cells in tumor tissues, while CD56+ natural killer cells and CD8+ T cells had lower infiltration. Tumor tissues with higher EGFR VAF were associated with lower cell infiltration such as CD3+ T cells, CD20+ B cells, CD56+ natural killer cells, CD68+ macrophages, CD8+ T cells, and only CD3+ T cells showed a lower spatial distribution heterogeneity. For the two common subtypes of EGFR mutations in Chinese population, tumor tissues with EGFR exon 19 deletion mutations have lower immune cell infiltration but higher spatial distribution heterogeneity of CD3+ T cells, CD56+ natural killer cells, CD68+ macrophages, and CD8+ T cells than that in EGFR exon 21 L858R mutant tumor tissues. Prognostic analysis found that patients with EGFR mutations with high degree of CD3+ T cells, CD20+ B cell infiltration and larger numbers of TLS formation and high spatial distribution heterogeneity of CD8+ T cell had longer disease-free survival. Conclusions: EGFR-mutated lung adenocarcinoma had a unique "non-inflammatory" tumor microenvironment with low infiltration of immune cells, and there was also heterogeneity in the tumor microenvironment among the tumors with different mutation subtypes and mutation abundance. These differences were not only reflected in the number but also the spatial distribution of immune cell infiltration. Hence, further studies on the immune microenvironment of EGFR-mutant lung adenocarcinoma were of great significance for improving the efficacy of immunotherapy in EGFR-mutant lung adenocarcinoma patients in the future.

Lung adenocarcinoma radiosensitivity depends on EGFR signaling pathway or other pathways? —— a research based on gene sequencing and data-independent acquisition (DIA) mass spectrometry

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index

Comparison of the Epidermal Growth Factor Receptor Protein Expression Between Primary Non-Small Cell Lung Cancer and Paired Lymph Node Metastases: Implications for Targeted Nuclide Radiotherapy.

A Prospective Comparison Study on EGFR Mutations by Direct Sequencing and ARMS in Completely Resected Chinese Non-Small Cell Lung Cancer with Adenocarcinoma Histology (ICAN).

Molecular mechanism of radiation tolerance in lung adenocarcinoma cells using single‐cell RNA sequencing

Gene Status and Clinicopathologic Characteristics of Lung Adeno-Carcinomas with Mediastinal Lymph Node Metastasis

Lung Adenocarcinoma Resistance to Therapy with EGFR‑tyrosine Kinase Inhibitors is Related to Increased Expression of Cancer Stem Cell Markers SOX2, OCT4 and NANOG.

Identification of Differentially Expressed Genes Related to Radioresistance of Human Esophageal Cancer Cells

Global profiling of transcriptome, proteome and 2-hydroxyisobutyrylome in radioresistant lung adenocarcinoma cell

Identification and Functional Characterization of Essential Genes Related to Gefitinib Sensitivity in Lung Adenocarcinoma

EEF1A2 and ERN2 could potentially discriminate metastatic status of mediastinal lymph node in lung adenocarcinomas harboring EGFR 19Del / L858R mutations

Characterization and Mechanisms of Radioresistant Lung Squamous Cell Carcinoma Cell Lines

[Correlation between Immune Microenvironment Features and EGFR Mutation Status in Lung Adenocarcinoma]

Varied Pathways of Stage Ia Lung Adenocarcinomas Discovered by Integrated Gene Expression Analysis

Expression patterns of platinum resistance-related genes in lung adenocarcinoma and related clinical value models

[Establishment of Human Lung Adenocarcinoma Radioresistant Cell Lines and the Mechanism of Radioresistance].

18F-Fluorodeoxyglucose Positron Emission Tomography/computed Tomography-Based Radiomic Features for Prediction of Epidermal Growth Factor Receptor Mutation Status and Prognosis in Patients with Lung Adenocarcinoma

Effect of EGFR Mutation on Radiation-Induced DNA Repair in Pulmonary Adenocarcinoma Cells

Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion